NASDAQ:DMPI - DelMar Pharmaceuticals Stock Price, Forecast & News

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

DelMar Pharmaceuticals shares reverse split on the morning of Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) issued its quarterly earnings data on Tuesday, September, 10th. The company reported ($0.89) EPS for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.59. View DelMar Pharmaceuticals' Earnings History.

DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for DelMar Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DelMar Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DelMar Pharmaceuticals.

Headlines about DMPI stock have been trending very positive on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DelMar Pharmaceuticals earned a coverage optimism score of 3.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for DelMar Pharmaceuticals.

DelMar Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 241,800 shares, an increase of 270.3% from the October 31st total of 65,300 shares. Based on an average trading volume of 568,300 shares, the days-to-cover ratio is presently 0.4 days. Approximately 9.9% of the shares of the company are sold short. View DelMar Pharmaceuticals' Current Options Chain.

Some companies that are related to DelMar Pharmaceuticals include Q BioMed (QBIO), Aptevo Therapeutics (APVO), Innovate Biopharmaceuticals (INNT), Provectus Biopharmaceuticals (PVCT), Kazia Therapeutics (KZIA), ContraFect (CFRX), Eyegate Pharmaceuticals (EYEG), Soligenix (SNGX), ProPhase Labs (PRPH), OncoSec Medical (ONCS), Melinta Therapeutics (MLNT), Acerus Pharmaceuticals (TRLPF), Bio-Path (BPTH), Aerpio Pharmaceuticals (ARPO) and Unum Therapeutics (UMRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other DelMar Pharmaceuticals investors own include Advanced Micro Devices (AMD), Sunworks (SUNW), Medical Properties Trust (MPW), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), BIOLINERX LTD/S (BLRX), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

DelMar Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (8.35%). View Institutional Ownership Trends for DelMar Pharmaceuticals.

DMPI stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for DelMar Pharmaceuticals.

Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DMPI stock can currently be purchased for approximately $0.62.

DelMar Pharmaceuticals has a market capitalization of $7.10 million. The company earns $-8,050,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. DelMar Pharmaceuticals employs 4 workers across the globe.View Additional Information About DelMar Pharmaceuticals.

The official website for DelMar Pharmaceuticals is http://www.delmarpharma.com/.

DelMar Pharmaceuticals' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-350-4364 or via email at [email protected]